Therapeutic radionuclides in nuclear medicine: current and future prospects  

核医学放射性核素治疗的研究现状及前景(英文)

作　　者：Chai-Hong YEONG Mu-hua CHENG Kwan-Hoong NG 

机构地区：[1]Department of Biomedical Imaging & University of Malaya Research Imaging Centre, Faculty of Medicine,University of Malaya [2]Department of Nuclear Medicine, the Third Affiliated Hospital, Sun Yat-Sen University

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2014年第10期845-863,共19页浙江大学学报（英文版）B辑（生物医学与生物技术）

摘　　要：The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131（^131I）, phosphorous-32（^32P）, strontium-90（^90Sr）, and yttrium-90（^90Y）, have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.放射性核素的临床应用及研究已历数十载,已有碘-131、磷-32、锶-90及钇-90等众多放射性核素被成功用于治疗良恶性疾病。随着新的放射性核素及药物不断应用于骨转移瘤疼痛治疗、神经内分泌肿瘤及其他良恶性肿瘤治疗,放射性核素治疗得到了快速发展。目前,放射性核素治疗已进入蓬勃发展期;在亚洲,由于甲状腺和肝脏肿瘤的高发病率,促进了放射性核素治疗及其靶向治疗研究的日益发展。随着放射性核素与其他药物的联合应用,放射性核素治疗肿瘤的临床价值必将显著提高。

关 键 词：Therapeutic radionuclide Targeted radionuclide therapy RADIOIMMUNOTHERAPY Molecular targeting THERANOSTICS 

分 类 号：R817[医药卫生—影像医学与核医学]